Free Trial

Allakos Q4 2023 Earnings Report

Allakos logo
$0.23 0.00 (-1.96%)
As of 03/28/2025 04:00 PM Eastern

Allakos EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Allakos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Allakos Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Allakos Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Allakos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Allakos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Allakos and other key companies, straight to your email.

About Allakos

Allakos (NASDAQ:ALLK), a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

View Allakos Profile

More Earnings Resources from MarketBeat